• About Us
    • What We Do
    • Our Story
    • Board Members
    • Management Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • Media
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Board Members
    • Management Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • Media
  • Contact

10 News First reports Ellume’s $42M NIH funding for rapid COVID test

8 October 2020, Samantha Butler

Ellume Founder, CEO and Managing Director Dr Sean Parsons was recently interviewed by 10 News First Queensland’s Samantha Butler on the successful awarding of $42m from the US NIH to Ellume to scale up and fast track the production of its COVID-19 diagnostic tests.

This interview originally appeared on 10 News First Queensland TV news on 8th October 2020. The story can also be viewed on on the 10 Play app.

Recent Posts
  • BBC World Service Radio Brisbane Interview with Ellume CEO
  • FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test
  • Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study
  • Palaszczuk Government boosts manufacturing capability for Ellume’s world-class COVID-19 rapid tests
  • ABC Radio “The Money” Interview with Ellume CEO, Dr Sean Parsons
Archives

Ellume awarded US$30M from US National Institutes of Health RADx initiative to accelerate development of rapid COVID-19 diagnostics

Previous thumb

Ellume enlists Bosch Australia to automate manufacturing for high-performance COVID-19 Test

Next thumb
Scroll

ellume logo white

ABN 13 141 767 660
57 Didsbury Street,
East Brisbane, Queensland 4169
Australia

MENU

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
Media

CONTACT US

1800 001 120
+61 7 3393 1448
General Enquiries
Privacy Policy
Whistleblower Policy

Some Ellume products are pending regulatory clearance – NOT AVAILABLE FOR SALE © Ellume Limited 2020